Prognostic of different glomerular filtration rate formulas in patients receiving percutaneous coronary intervention: insights from a multicenter observational cohort

Wei Chen¹, Pengyuan Chen²†, Zhonghan Ni³†, Yuanhui Liu³, Wei Guo³, Lei Jiang³, Xuebiao Wei³, Jiyan Chen³, Ning Tan³, Pengcheng He²,³* and Yansong Guo¹*†

Abstract
Background: The relationships of renal dysfunction (RD) and chronic kidney disease (CKD) with prognosis have been well established among non-ST elevation acute coronary syndrome (NSTE-ACS) patients who receive percutaneous coronary intervention (PCI), but the efficacy of different estimated glomerular filtration rate (eGFR) formulas for predicting the prognosis is unknown.

Methods: The cohort originated from a retrospective data, which consecutively enrolled 8197 patients. The eGFR was calculated by the Cockcroft-Gault, Modification of Diet in Renal Disease (MDRD), CKD Epidemiology Collaboration-creatinine, CKD Epidemiology Collaboration-Cys-C, CKD Epidemiology Collaboration-Cys-C-creatinine and a modified abbreviated MDRD (c-aGFR) equations in Chinese CKD patients. Patients were excluded if the eGFR could not be obtained by one of the formulas. Patients were categorized as having normal renal function, mild RD, moderate RD, severe RD, or kidney failure to compare prognosis. The primary outcome was the in-hospital net adverse clinical events (NACE). The secondary outcomes were NACE and all-cause death during follow-up.

(Continued on next page)
Results: In total, 2159 NSTE-ACS patients (age: 64.23 ± 10.25 years; males: 73.7%) were enrolled. 39 (1.8%) patients with in-hospital NACE were observed. During the 3.23 ± 1.55-year follow-up, 1.7% death and 4.2% NACE were observed in 1 year. The percentage of severe RD patients ranged from 15.4 to 39.2% according to different calculation formulas. A high prevalence of in-hospital NACE was observed in the severe RD groups (ranging from 8 to 14.3% for different formulas). Multiple regression analysis showed that a high eGFR is a protect factor against NACE and all-cause death regardless of the formula use. Receiver operating characteristic curves showed similar predictive performance of the c-aGFR when compared to other formulas (in-hospital NACE: AUC = 0.612, follow-up NACE: AUC = 0.622, and follow-up death: AUC = 0.711).

Conclusions: Severe RD results in a high prevalence of in-hospital NACE in NSTE-ACS patients after PCI regardless of the formulas use. Different formulas have a similar ability to predict in-hospital and long-term prognosis in NSTE-ACS patients. The c-aGFR formula is the simplest and a more convenient formula for use in practice.

Keywords: Non-ST elevation acute coronary syndrome, Percutaneous coronary intervention, Renal dysfunction, Prognosis
min per 1.73 m²), mild RD (eGFR, 60–90 ml/min per 1.73 m²), moderate RD (30–59 ml/min per 1.73 m²), severe RD (15–29 ml/min per 1.73 m²), or kidney failure (< 15 ml/min per 1.73 m²).

The primary endpoint was the in-hospital net adverse clinical events (NACE), which includes all-cause death, myocardial infarction and major bleeding (Bleeding Academic Research Consortium (BARC) score > 2), [13], the secondary outcomes were all-cause death as well as the NACE during the 1-year follow-up.

All data analyses were performed using SAS (version 9.4, SAS Institute, 210 Cary, North Carolina, USA), and a P value of less than 0.05 was considered as statistically significant. Categorical variables are expressed as counts (proportions), and differences among the groups were assessed using a chi-square test or Fisher’s exact probability method. Variables with a non-normal distribution are presented as the medians and IQRs. Continuous variables with a normal distribution are presented as the mean ± standard deviations. Differences among the groups were assessed using a t test or the Mann-Whitney U test for statistical analysis. Univariate analysis and multivariate logistic regression analyses were performed to calculate the adjusted odds ratios (ORs) and Hazard ratios (HRs) with 95% confidence intervals (CIs) for in-hospital mortality and NACE according to the

**Fig. 1** Flowchart of the study. ACS: acute coronary syndrome; PCI: percutaneous coronary intervention; STEMI: ST-segment elevation myocardial infarction; IABP: intra-aortic balloon pump; eGFR: estimated glomerular filtration rate.
EeGFR (adjusted for sex, anemia, left main coronary artery stenosis, congestive heart failure, diagnosis (UA or NSTEMI), prior myocardial infarction (MI), prior stroke, stent number, stent length). The Kaplan–Meier method and log-rank test were used to analyze the all-cause mortality during the follow-up period. The area under each receiver operating characteristic curve (AUC) was calculated to assess the discriminative performance of each formula. All the missing data were eliminated.

Results
Of all the 2159 NSTE-ACS patients, 39 (1.8%) patients with in-hospital NACE were observed. The clinical baseline characteristics of the patients between NACE and non-NACE are shown in Table 1. A total of 2159 patients were included in the study, of whom the mean age was 64.23 ± 10.25, 1591 (73.7%) were male. Patients with NACE were elder, have a higher rate of female, chronic heart failure and chronic kidney disease. They received more CCB, nitric acid, tirofiban and PCI stent. Notably, the serum creatinine and eGFR of the five formulas were all higher in the NACE patients’ group.

The prevalence of significant RD, as identified by an eGFR of less than 60 ml/min/1.73 m², ranged from a minimum of 15.4% using the c-aGFR formula to a maximum of 39.2% using the CKD-EPIcr-Cys-C formula, with the other formulas providing intermediate values (CG 33%, CKD-EPIcr 20.4%, CKD-EPI_Cys-C 34.7%). The average eGFR values were 86.98 ± 29.53(c-aGFR), 73.03 ± 27.93(CG), 77.18 ± 21.52(CKD-EPIcr), 71.72 ± 26.44(CKD-EPI_Cys-C), and 65.70 ± 21.18(CKD-EPIcr_Cys-C) ml / min / 1.73 m² respectively (Table Appendix 1 in the supplemental materials).

The incidence rates of in-hospital NACE for different grades of renal function according to the various formulas are shown in Fig. 2 (Table Appendix 2 in the supplemental materials). Logistic regression analysis showed that a high eGFR is a protective factor against in-hospital NACE as well as follow-up NACE or death (Table 2). Five formulas showed the same discriminatory capacity for predicting NACE in the entire population, with AUC values of 0.612(c-aGFR), 0.658(CG), 0.645(CKD-EPIcr), 0.608(CKD-EPI_Cys-C), and 0.630(CKD-EPIcr_Cys-C) respectively (Fig. 3a).

During the 3.23 ± 1.55-year follow-up, 1.7% death and 4.2% NACE were observed in 1 year. Kaplan–Meier survival analyses of death and NACE within 1 year categorized by renal function status according to the 5 different formulas are shown in Fig. 4. A total of 154 patients died during the 3 years of follow-up. All 5 formulas yielded similar trends in mortality and incidence rates. CKD staged by the 5 formulas was related to increased rates of mortality and NACE. The results of multivariable model and Cox regression fitting for the prediction of death and NACE using the various formulas are shown in Table 2. Regardless of the formula used, the risk of death for patients with a low glomerular filtration rate was always higher, and all formulas predicted death and secondary endpoints. The discriminatory power of each formula was assessed by calculating the AUC for the in-hospital NACE and death and NACE within 1 year (Fig. 3b and c).

Discussion
This study showed the following results. First, although the glomerular filtration rates calculated by the five formulas were different and the proportion of each eGFR categorization varied markedly, the predictive value for the prognosis was consistent. Second, consistent with other studies, our study also found that RD is a good prognostic factor for NSTE-ACS patients undergoing PCI. Third, the c-aGFR formula, including only age and the serum creatinine level, is sufficient and practical for the prediction of eGFR compared to other formulas that include Cys-C.

Renal insufficiency is a predictor of coronary heart disease prognosis. However, there is no indicator in clinical work that can accurately reflect renal function, including creatinine and Cys-C. When the kidney damage affects more than half of the entire kidney, serum creatinine will increase. The blood concentration of Cys-C is dependent on glomerular filtration without including any external factors, such as sex, age, or diet [14]. Cys-C is considered by many studies to be a relatively early and more sensitive marker than creatinine for indicating changes in renal function, but it is not measured in many hospitals. Creatinine clearance is the gold standard for assessing kidney function, but its detection is very complex and is only used for scientific research. Therefore, many evaluation formulas based on clinical indicators have been proposed. Renal function, which can be derived from different GFR evaluation formulas is considered a major risk factor for cardiovascular complications in patients with ACS [15].

Several studies have focused on assessing the prognostic value of eGFR formulas in different clinical situations. In the TRILOGY ACS Trial [2], Chiara Melloni et al. evaluated 8953 patients with ACS and found that worse CKD staging was significantly related to increased long-term risks of ischemic and bleeding outcomes. Conversely, in a recent registry study involving 1699 ACS patients, the CG equation presented a superior predictive ability for major adverse cardiovascular events to the MDRD-4 equation and was superior to the CKD-EPI equation [16]. Therefore, the difference between the predictive values of the CG formula and the CKD-EPI formula for prognosis showed mixed results.

Renal function is considered a major risk factor for cardiovascular complications in patients with ACS [15].
### Table 1 Baseline characteristics between patients with NACE and non-NACE

| Characteristic                     | Total  
|-----------------------------------|--------|
|                                   | (n = 2159) | non-NACE   | NACE   | P value |
| Age (year)                        | 64.23 ± 10.25 | 64.12 ± 10.26 | 70.15 ± 7.75 | < 0.001 |
| Age ≥ 65 years                    | 1086 (50.3%) | 1058 (49.9%) | 28 (71.8%) | 0.007  |
| Weight (kg)                       | 66.49 ± 12.14 | 66.55 ± 11.93 | 63.25 ± 20.55 | 0.323  |
| Male sex                          | 1591 (73.7%) | 1569 (74.0%) | 22 (56.4%) | 0.013  |
| Smoking                           | 601 (27.8%) | 590 (27.8%) | 11 (28.2%) | 0.959  |
| CHF                               | 274 (12.7%) | 264 (12.5%) | 10 (25.6%) | 0.014  |
| CKD                               | 382 (17.7%) | 370 (17.5%) | 12 (30.8%) | 0.031  |
| MI history                         | 342 (15.8%) | 334 (15.8%) | 8 (20.5%) | 0.420  |
| Prior PCI                          | 400 (18.5%) | 397 (18.7%) | 3 (7.7%) | 0.079  |
| Prior CABG                         | 22 (1.0%) | 22 (1.0%) | 0 (0.0%) | 0.523  |
| Stroke                            | 160 (7.4%) | 158 (7.5%) | 2 (5.1%) | 0.583  |
| Atrial fibrillation                | 71 (3.3%) | 70 (3.3%) | 1 (2.6%) | 0.798  |
| Hypertension                      | 1490 (69.0%) | 1463 (69.0%) | 27 (69.2%) | 0.976  |
| Diabetes mellitus                 | 715 (33.1%) | 698 (32.9%) | 17 (43.6%) | 0.301  |
| Hyperlipemia                      | 473 (21.9%) | 462 (21.8%) | 11 (28.2%) | 0.337  |
| Clopigel/Ticagrelor               | 2130 (99.1%) | 2100 (99.1%) | 30 (100.0%) | 0.553  |
| Aspirin loading                   | 554 (25.7%) | 534 (25.2%) | 20 (51.3%) | < 0.001 |
| Cilostazol                        | 52 (2.4%) | 50 (2.4%) | 2 (6.0%) | 0.007  |
| Statin                            | 2133 (98.5%) | 2085 (98.4%) | 38 (100.0%) | 0.438  |
| DAPT                              | 2092 (97.0%) | 2054 (97.0%) | 38 (97.4%) | 0.881  |
| Warfarin                          | 13 (0.6%) | 13 (0.6%) | 0 (0.0%) | 0.624  |
| ACE/ARB                           | 1650 (76.5%) | 1622 (76.5%) | 28 (71.8%) | 0.488  |
| CCB                               | 544 (25.2%) | 527 (24.9%) | 17 (43.6%) | 0.008  |
| Nitric acid merged                | 1294 (60.0%) | 1262 (59.6%) | 32 (82.1%) | 0.004  |
| Beta blockers                     | 1804 (83.6%) | 1770 (83.5%) | 34 (87.2%) | 0.542  |
| Tirofibran                        | 204 (9.4%) | 192 (9.1%) | 12 (30.8%) | < 0.001 |
| Number of stents                  | 2 (1 ~ 3) | 2 (1 ~ 3) | 2 (1 ~ 3) | 0.047  |
| Total length of stents (mm)       | 39 (24 ~ 66) | 38 (24 ~ 65) | 51 (33 ~ 84) | 0.023  |
| Diagnosis                         |                      |                  |        | 0.472  |
| Unstable angina                   | 1227 (56.9%) | 1207 (57.0%) | 20 (51.3%) |        |
| NSTEMI                            | 928 (43.1%) | 909 (43.0%) | 19 (48.7%) |        |
| Cys-c (mg/L)                      | 1.20 ± 1.77 | 1.19 ± 1.78 | 1.44 ± 0.98 | 0.138  |
| Creatinin (μmol/L)                | 94.14 ± 69.35 | 93.47 ± 66.16 | 130.28 ± 166.34 | 0.176  |
| Estimated GFR (ml/min/1.73 m²)    |                      |                  |        |        |
| c-aGFR                            | 86.98 ± 29.53 | 87.19 ± 29.45 | 75.18 ± 32.21 | 0.012  |
| CG                                | 73.03 ± 27.93 | 73.31 ± 27.88 | 57.71 ± 26.58 | 0.001  |
| CKD-EPlcr                         | 77.18 ± 21.52 | 77.40 ± 21.41 | 65.37 ± 24.65 | 0.001  |
| CKD-EPlcr<sub>CG</sub>            | 71.72 ± 26.44 | 71.91 ± 26.36 | 61.23 ± 29.33 | 0.012  |
| CKD-EPlcr<sub>Cys-c</sub>        | 65.70 ± 21.18 | 65.90 ± 21.10 | 55.16 ± 23.13 | 0.002  |

**Notes:**
- CHF: chronic heart failure, CKD: chronic kidney disease, MI: myocardial infarction, PCI: percutaneous coronary intervention, CABG: coronary artery bypass grafting, DAPT: dual antiplatelet therapy, ACEI/ARB: aldosterone receptor inhibitors and aldosterone receptor antagonist, CCB: calcium channel blocker, NSTEMI: non-ST segment elevation myocardial infarction, eGFR: estimated glomerular filtration rate
Fig. 2 Incidence of in-hospital NACE based on renal function risk classification of different eGFR formulas. * indicates the $P < 0.001$; # indicates the $P < 0.05$

Table 2 Univariate and Multivariable Logistic or Cox Regression Risk Analysis for Prediction of Death and NACE

|                    | Univariate |                |                | Multivariate |                |                |
|--------------------|------------|----------------|----------------|--------------|----------------|----------------|
|                    | Odds or Hazard Ratio(95%CI) | $P$ Value | Odds or Hazard Ratio(95%CI) | $P$ Value |
| **In hospital NACE** |            |                |                |              |                |                |
| c-aGFR             | 0.99 (0.97 ~ 1.00) | 0.010          | 0.98 (0.97 ~ 1.00) | 0.012        |
| CG                 | 0.98 (0.96 ~ 0.99) | < 0.001        | 0.98 (0.96 ~ 0.99) | 0.002        |
| CKD-EPlcr          | 0.98 (0.97 ~ 0.99) | 0.001          | 0.98 (0.96 ~ 0.99) | 0.002        |
| CKD-EPI Cys-C      | 0.98 (0.97 ~ 1.00) | 0.013          | 0.99 (0.97 ~ 1.00) | 0.049        |
| CKD-EPI Cys-C      | 0.98 (0.96 ~ 0.99) | 0.002          | 0.98 (0.96 ~ 0.99) | 0.008        |
| **1-year NACE**    |            |                |                |              |                |                |
| c-aGFR             | 0.98 (0.97 ~ 0.99) | < 0.001        | 0.99 (0.98 ~ 1.00) | 0.004        |
| CG                 | 0.97 (0.96 ~ 0.98) | < 0.001        | 0.98 (0.97 ~ 0.99) | < 0.001      |
| CKD-EPlcr          | 0.97 (0.96 ~ 0.98) | < 0.001        | 0.98 (0.97 ~ 0.99) | < 0.001      |
| CKD-EPI Cys-C      | 0.98 (0.97 ~ 0.99) | < 0.001        | 0.99 (0.98 ~ 1.00) | 0.012        |
| CKD-EPI Cys-C      | 0.97 (0.96 ~ 0.98) | < 0.001        | 0.98 (0.97 ~ 0.99) | < 0.001      |
| **1-year death**   |            |                |                |              |                |                |
| c-aGFR             | 0.97 (0.96 ~ 0.98) | < 0.001        | 0.98 (0.97 ~ 0.99) | < 0.001      |
| CG                 | 0.97 (0.94 ~ 0.97) | < 0.001        | 0.97 (0.95 ~ 0.98) | < 0.001      |
| CKD-EPlcr          | 0.96 (0.95 ~ 0.97) | < 0.001        | 0.97 (0.96 ~ 0.99) | < 0.001      |
| CKD-EPI Cys-C      | 0.96 (0.95 ~ 0.98) | < 0.001        | 0.98 (0.96 ~ 0.99) | < 0.001      |
| CKD-EPI Cys-C      | 0.96 (0.94 ~ 0.97) | < 0.001        | 0.97 (0.95 ~ 0.98) | < 0.001      |

Abbreviations: CI confidence interval; Adjusted for sex, anemia, left main coronary artery stenosis, congestive heart failure, diagnosis (UA or NSTEMI), prior-MI and prior-stroke. All 5 equations were tested separately.
However, the conclusions of different studies vary regarding which formula has the best correlation with prognosis. Piercarlo Ballo et al. followed 222 NSTE-ACS patients who underwent PCI, for 10 years to compare the predictive value of four creatinine-based eGFR formulas (CG, MDRD, CKD-EPI and Mayo-Quadratic). The Mayo-Quadratic formula was the best predictor of mortality, while the CKD-EPI formula showed the best performance in predicting cardiovascular events [7]. Katia Orvin et al. also suggested that the Mayo-Quadratic formula had better accuracy in predicting mortality than the MDRD, CG, CKD-EPI, and IB (an inulin clearance–based eGFR formula) formulas in patients with ACS [17]. The HOMAGE study, which used the CG formula adjusted for BSA, revealed a slight superiority in predicting cardiovascular mortality over the CKD-EPI and MDRD4 formulas in population with cardiovascular risk, heart failure and MI, but this advantage was not obvious in the general population [18]. Inês Almeida retrospectively assessed eGFR with the MDRD, CKD-EPIcreat, CKD-EPIcyst and CKD-EPIcreat/cyst formulas and suggested that the CKD-EPIcyst equation was superior to the MDRD formula for evaluating the mid-term mortality risk in patients admitted for ACS and added prognostic power to the GRACE score [19]. Conversely, in another larger sample size study, Axel Akerblom analyzed data from 13,632 patients in the PLATO study and found no difference in prognostic values for risk prediction of Cys-C- and creatinine-based formulas [17].

The simplified MDRD formula includes only 4 variables: sex, age, creatinine, and race; no difference in accuracy was found compared with other formulas recommended by the US CKD and dialysis clinical practice (K/DOQI) guidelines. The renal tubular secretion of creatinine differs in the Asian population, which exhibits differences in racial background and muscle mass. The national eGFR research team developed an improved original abbreviated MDRD formula (c-aGFR) based on the relevant data of 684 CKD patients in 2006, which showed smaller deviations and higher accuracy in Chinese CKD patients [20].

However, the current study focused on NSTE-ACS patients with PCI. These patients tended to be older, have more comorbidities (including worse renal function) and have worse long-term prognosis than ST segment elevation ACS patients [21]. Therefore, accurate long-term risk stratification of NSTE-ACS patients is even more crucial. Our study may therefore show that the five formulas have similar prognostic value for NSTE-ACS patients. Based on the original abbreviated MDRD formula, the c-aGFR formula is the simplest among the 5 formulas, can be easily used for the assessment of CKD patients [14] and is sufficient for assessing the prognosis of NSTE-ACS patients. Patients may not need to undergo Cys-C assessment as a routine clinical practice. Although a significant difference was observed between the CKD-EPI_Cys-C formula and combined CKD-EPI formula for predicting mortality, the range of superiority was limited. Additionally, according to our findings, the CKD-EPI_Cys-C formula may result in an overestimation of renal dysfunction, which does not affect the long-term prognosis.

Limitations

There are some limitations of our research. First, our study is a retrospective cohort study with inherent limitations. Second, the estimation of GFR in this study is based on the creatinine value at admission. Importantly, creatinine may vary significantly in patients with ACS;
therefore, the eGFR may be unstable. Third and notably, this study was conducted in NSTE-ACS patients undergoing PCI procedures, and therefore, our results cannot be extrapolated to patients who did not receive PCI. However, the PCI procedure has been recommended as a priority treatment among NSTE-ACS patients in the current guidelines. The current findings may be applicable to most current patients.

Fig. 4 Kaplan-Meier survival curves for death (a) and NACE (b) within 1 year for different eGFR formulas.
Conclusion
Among NSTE-ACS patients who received PCI, those with severe RD exhibited a high prevalence of in-hospital NACE as well as follow-up NACE and death regardless of the formula used to calculate the eGFR. All five eGFR assessment formulas can be used to evaluate the prognosis of ACS patients and have similar predictive value. The c-aGFR, the simplest formula for assessing eGFR and is sufficient and practical for prognosis prediction in clinical work.

Supplementary information
Supplementary information accompanies this paper at https://doi.org/10.1186/s12872-020-01621-y.

Additional file 1.

Abbreviations
AUC: Area under the curve; BARC: Bleeding academic research consortium; c-aGFR: A modified abbreviated MDRD equation based on the Chinese CKD patients; CdG: Cockroft-Gault; Cis: 95% confidence intervals; CKD-EPI-cysC: CKD epidemiology collaboration-creatinine; CKD-EPI-cysC: CKD epidemiology collaboration- Cystatin C; CKD-EPI-cysC: CKD epidemiology collaboration- Cys-C creatinine; CRD: Chronic kidney disease; eGFR: Estimated glomerular filtration rate; HRs: Hazard ratios; KDIGO: The US CKD and dialysis clinical practice guidelines; MDRD: Modification of diet in renal disease; NACE: Net adverse clinical events; NSTE-ACS: Non-ST elevation acute coronary syndrome; ORs: Odds ratios; PCI: Percutaneous coronary intervention; RD: Renal dysfunction; UA: Unstable angina pectoris

Acknowledgements
Not applicable.

Authors' contributions
Conceptualization, G.Y. and H.P; methodology, C.W., software, C.P. and L.Y; validation, T.N. and C.J; formal analysis, L.Y.; investigation, N.Z and W.X.; resources, G.W.; data curation, J.L.; writing—original draft preparation, C.W., C.P. and N.Z.; writing—review and editing, G.Y.; visualization, G.Y.; supervision, G.Y.; project administration, G.Y. and H.P.; funding acquisition, G.Y. All authors have read and approved the manuscript.

Funding
This study was supported by the Outstanding Young Talent Program of Guangdong Provincial People’s Hospital (grant number: KJ012019084), National Natural Science Foundation of China General Program (No. 81873495), Natural Science Foundation of Fujian Province (grant No. 2018 J01242) and Fujian Provincial Health Commission Youth Key Talents Project (Key Category) (No. 2014-ZQN-2D-2). The funders had no role in the design of the study, the data collection and analysis, the decision to publish, or the preparation of the manuscript. The work was not funded by any industry sponsors. The authors have no other conflicts that need to be disclosed.

Availability of data and materials
The datasets used and analyzed during the current study are available from the corresponding author on reasonable request.

Ethics approval and consent to participate
The study protocol was approved by the central ethics committee of the Guangdong Provincial People’s Hospital (NO. GDREC2016210H(R1)). Patients were included with a waiver of informed consent.

Consent for publication
Not applicable.

Competing interests
The authors declare that there is no conflict of interest.

Author details
1 Clinical College of Fujian Provincial Hospital, Fujian Provincial Hospital Key Laboratory of Cardiovascular Disease, Fujian Provincial Center for Geriatrics, Fujian Medical University, Fujian Cardiovascular Institute, Fuzhou 350001, China. 2 Department of Cardiology, Guangdong Provincial People’s Hospital’s Nanhai Hospital, The Second Hospital of Nanhai District Foshan City, Foshan 528000, China. 3 Department of Cardiology, Guangdong Cardiovascular Institute, Guangdong Provincial Key Laboratory of Coronary Heart Disease Prevention, Guangdong Provincial People’s Hospital, Guangdong Academy of Medical Sciences, Guangzhou 510100, China.

Received: 12 April 2020 Accepted: 13 July 2020
Published online: 18 July 2020

References
1. Anavekar NS, McMurray JJ, Velazquez EJ, et al. Relation between renal dysfunction and cardiovascular outcomes after myocardial infarction. N Engl J Med. 2004;351:1285–95.
2. Melloni C, Corneli JH, Haffey G, et al. Impact of chronic kidney disease on long-term ischemic and bleeding outcomes in medically managed patients with acute coronary syndromes: insights from the TRILOGY ACS trial. Eur Heart J. 2015;643–54.
3. Al SJ, Reddan DN, Williams K, et al. Prognostic implications of abnormalities in renal function in patients with acute coronary syndromes. Circulation. 2002;106:974–80.
4. Fox CS, Muntner P, Chen AY, et al. Use of evidence-based therapies in and short-term outcomes of STEMI and NSTEMI in patients with chronic kidney disease: a report from the National Cardiovascular Data ACTION registry. Circulation. 2010;121(3):357–65.
5. Stevens LA, Coresh J, Greene T, et al. Assessing kidney function—measured and estimated glomerular filtration rate. N Engl J Med. 2006;355:2473–83.
6. Roffi M, Patrono C, Collet JP, et al. 2015 ESC guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: task force for the Management of Acute Coronary Syndromes in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J. 2016;37(3):267–315.
7. Zamora E, Lupon J, de Antonio M, et al. Long-term prognostic value for patients with chronic heart failure of estimated glomerular filtration rate calculated with the new CKD-EPI equations containing Cys-C. Clin Chem. 2014;60(3):481–9.
8. Ballo P, Chechi T, Spaziani G, et al. Prognostic comparison between creatinine-based glomerular filtration rate formulas for the prediction of 10-year outcome in patients with non-ST elevation acute coronary syndrome treated by percutaneous coronary intervention. Eur Heart J. 2016;37(3):375–83.
9. Zummer K, Lundman P, Jacobson SH, et al. Cockcroft-Gault is better than the modification of diet in Renal disease study formula at predicting outcome after a myocardial infarction: data from the Swedish web-system for enhancement and development of evidence-based care in heart disease evaluated according to recommended therapies (SWEDHEART). Am Heart J. 2010;159:797–86.
10. Flores-Blanco PJ, Lopez-Cuenca A, Januzzi JL, et al. Comparison of risk prediction with the CKD-EPI and MDRD equations in non—ST-segment elevation acute coronary syndrome. Clin Cardiol. 2016;39(9):507–15.
11. Chen J, He P, Liu Y, et al. Association of Parenteral Anticoagulation Therapy with Outcomes in Chinese patients undergoing percutaneous coronary intervention for non—ST-segment elevation acute coronary syndrome. JAMA Intern Med. 2019;179(2):188.
12. Stevens PE, Levin A. Evaluation and management of chronic kidney disease: synopsis of the kidney disease: improving global outcomes 2012 clinical practice guideline. Ann Intern Med. 2013;158(11):825–30.
13. Mehran R, Rao SV, Bhatt DL, et al. Standardized bleeding definitions for cardiovascular clinical trials: a consensus report from the bleeding academic research consortium. Circulation. 2011;123(2):2736–47.
14. Tagliari N, Koenig W, Kaski J. Cys-C and cardiovascular risk. Clin Chem. 2009;55:1932–43.
15. Ozenbaum Z, Benchettrit S, Minha S, et al. The effect of admission renal function on the treatment and outcome of patients with acute coronary syndrome. Cardiol Rev. 2017;7:169–78.
16. Rivera-Caravaca JM, Ruiz-Nodar JM, Tello-Montoliu A, et al. Low body weight and clinical outcomes in acute coronary syndrome patients: results of the ACHILLES registry. Eur J Cardiovasc Nurs. 2017;16:696–703.

17. Orvin K, Eisen A, Goldenberg I, et al. The proxy of renal function that most accurately predicts short- and long-term outcome after acute coronary syndrome. Am Heart J. 2015;169(5):702–71.

18. Ferreira JP, Gireed N, Pellicori P, et al. Renal function estimation and Cockcroft-Gault formulas for predicting cardiovascular mortality in population based, cardiovascular risk, heart failure and post-myocardial infarction cohorts: The Heart ‘Omics’ in AGEing (HOMAGE) and the high-risk myocardial infarction database initiatives. BMC Med. 2016;14(1):181.

19. Almeida I, Caetano F, Barra S, et al. Estimating glomerular filtration rate in acute coronary syndromes: different equations, different mortality risk prediction. Eur Heart J Acute Cardiovasc Care. 2016;5(3):223–30.

20. Kong X, Ma Y, Chen J, et al. Evaluation of the chronic kidney disease epidemiology collaboration equation for estimating glomerular filtration rate in the Chinese population. Nephrol Dial Transplant. 2013;28(3):641–51.

21. Akerblom A, Wallentin L, Larsson A, et al. Cystatin C- and creatinine-based estimates of renal function and their value for risk prediction in patients with acute coronary syndrome: results from the PLATelet Inhibition and Patient Outcomes (PLATO) study. Clin Chem. 2013;59(9):1369–75.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.